To view or add a comment, sign in Eli Lilly and Company Reports Additional Positive Phase 3 Results for Retatrutide Across Multiple Obesity-Related Conditions On June 6, Eli Lilly and Company announced additional positive pivotal Phase 3 results for its investigational GLP-1/GIP/GCG triple receptor agonist, #Retatrutide
If eligible, we'll provide the prescription treatment options you need to accomplish your goals
Alas, many cant afford it
In: Feldman: Sleisenger and Fordtrans Gastrointestinal and Liver Disease, 9th ed
Room Temperature Limits by Medication After Opening and The First Dose is Taken: Semaglutide (Wegovy : Up to ) 28 days at room temperature (max 86F ) Semaglutide (Ozempic Up to ): 56 days at room temperature (max 86F ) Tirzepatide (Mounjaro : Up to /Zepbound ) 21 days at room temperature (max 86F ) Liraglutide (Saxenda : Up to ) 30 days at room temperature (max 86F ) Its important to note that if your medication has been exposed to extreme temperatures, frozen or you're unsure about storage conditions, consult your doctor before your next dose
Wall Street Analysts Goldman Sachs predicts that the oral GLP-1s (including oral Wegovy, Lillys orforglipron, and other pipeline products) will capture only a combined 24% of the GLP-1 market by 2030